Addario Lung Cancer Medical Institute - ALCMI

10/09/2025

At the ASTRO 2025 Annual Meeting, Dr. Joshua Meyer and colleagues at Fox Chase Cancer Center presented phase I trial results showing that pulsed low dose rate (PLDR) radiation—delivered alongside standard chemotherapy—significantly reduces toxicity without compromising efficacy.

Researchers at Fox Chase Cancer Center have demonstrated that pulsed low dose rate (PLDR) chemoradiation therapy can significantly reduce side effects while maintaining treatment effectiveness for patients with esophageal cancer and non-small cell lung cancer.

10/08/2025

Stereotactic radiation therapy offers long-term survival outcomes comparable to surgery for patients with small, early-stage non-small cell lung cancer (NSCLC), according to MD Anderson Cancer Center's Dr. Joe Chang and the STARS trial.

Long-term data from the STARS trial affirm stereotactic radiation as a strong alternative to surgery for patients with operable stage I NSCLC.

10/07/2025

Lung cancer now boasts one of the most robust portfolios of actionable biomarkers in oncology, according to Ed Kim, MD, MBA, and Neel Shah, MD.

Edward S. Kim, MD, MBA, and Neel Shah, MD, discuss advancing lung cancer care and tackling real-world access barriers for community physicians in the Treating Together podcast.

10/06/2025

Zipalertinib, an oral EGFR TKI, has demonstrated clinically meaningful efficacy with a manageable safety profile in patients with EGFR exon 20 insertion–mutated non–small cell lung cancer, according to Helena Yu, MD, from Memorial Sloan Kettering Cancer Center.

10/05/2025

Kwame Adjei, PharmD, Ph.D., Vakaramoko Diaby, Meng Li, Fatimah Sherbeny, PharmD, MS, PhD, Sandra Suther, and Askal Ali have delivered the most comprehensive synthesis to date on how real option value (ROV) is being applied to oncology.

The ROV represents a critical dimension in evaluating medical technologies in oncology, where innovation is rapid. The implications of ROV extend beyond oncology, with the potential to influence funding, pricing, and access decisions in other disease areas as well. However, challenges such as oversi...

10/04/2025

The nihilism surrounding SCLC is being dismantled by data, biology, and a renewed commitment to inclusive research.

Clinical trials in small cell lung cancer appear to be more “pragmatic” with their inclusion criteria than before, according to Anne Chiang, MD, PhD.

10/03/2025

Patients with poor performance status, who represent up to 88% of real-world cases, are routinely excluded from the pivotal trials that defined chemoimmunotherapy as the standard of care.

The addition of immune checkpoint inhibitors (ICI) to first-line platinum-doublet chemotherapy has substantially improved long-term outcomes in a subset of patients with extensive-stage small-cell lung cancer (SCLC), with 3-year survival rates reaching 16–18%, compared with approximately 6% with c...

10/02/2025

In a retrospective study from Saitama Medical Center, Saitama Medical University evaluated 74 patients with ECOG-PS 2–3 and found that adding an immune checkpoint inhibitor to platinum-based doublet chemotherapy increased median overall survival from 169 to 446 days.

Atezolizumab or durvalumab, combined with platinum-doublet regimens, delivered superior responses and survival in patients often excluded from clinical trials.

10/01/2025

In a real-world cohort study led by Kirsi Hormalainen and colleagues at Tampere University Hospital, comprehensive genomic profiling revealed clinically actionable mutations in 45% of NSCLC cases.

CGP affects the treatment strategies for NSCLC. Nearly half of our entire cohort had a genetic alteration eligible for approved targeted therapies. Besides these findings, CGP provides additional data to assess treatment decisions and outcomes, including co-occurring genetic alterations and TMB. In....

09/30/2025

In Cancer Discovery, Rocio Sotillo, PhD, and colleagues from the DKFZ German Cancer Research Center and Stanford University found that the specific variant of the EML4-ALK fusion in lung cancer dictates tumor aggression and response to targeted therapies.

About 5% of lung adenocarcinomas, one of the most common forms of lung cancer, are driven by a faulty fusion of two genes, EML4 and ALK. This fusion results in different variants, and until now, clinicians have treated all patients with these fusions the same way.

09/29/2025

Andrea Eleazar, MHS, and Kelly Paulson, MD, PhD, report in Targeted Oncology on results from the phase 1b DeLLphi-303 trial evaluating tarlatamab in combination with PD-L1 checkpoint inhibitors as maintenance therapy for extensive-stage small cell lung cancer (ES-SCLC).

New research highlights the promising combination of tarlatamab and checkpoint inhibitors, showing improved survival rates in extensive-stage small cell lung cancer patients.

09/28/2025

Dr. Adrien Rousseau, and colleagues at ALCMI consortium member Gustave Roussy have found that some medications taken at the beginning of immunotherapy can negatively impact survival in NSCLC patients.

Patients with advanced non-small cell lung cancer were negatively affected by exposure to antibiotics, PPIs, and high-dose steroids at the start of treatment with Keytruda (pembrolizumab), French researchers found.